In Roche’s rosy pandemic scenario, it will take a $2B hit to COVID sales this yearnews2022-02-03T21:03:11+00:00February 3rd, 2022|Fierce Pharma|
Roche, Novartis CEOs pull down $12M-plus each in 2021 paynews2022-02-03T20:41:38+00:00February 3rd, 2022|Fierce Pharma|
Connected TV works ‘harder and smarter’ for the ad dollar, new analysis findsnews2022-02-03T20:35:14+00:00February 3rd, 2022|Fierce Pharma|
Sanofi launches new corporate brand and logo, and that goes for Genzyme and Sanofi Pasteur, toonews2022-02-03T16:42:14+00:00February 3rd, 2022|Fierce Pharma|
Roche revs up new launches—and a slew of data readouts—as it emerges from the biosim troughnews2022-02-03T16:39:37+00:00February 3rd, 2022|Fierce Pharma|
Eli Lilly nixes Verzenio’s phase 3 HER2-positive early breast cancer trialnews2022-02-03T16:26:02+00:00February 3rd, 2022|Fierce Pharma|
Pfizer’s oral antiviral might be better, but Merck still expects $5B-plus from molnupiravir in 2022news2022-02-03T16:01:02+00:00February 3rd, 2022|Fierce Pharma|
Takeda’s Sequeira to head up newly created global portfolio division, Kim to lead US unitnews2022-02-03T15:28:47+00:00February 3rd, 2022|Fierce Pharma|
B. Braun gets FDA nod for new IV manufacturing site in Florida amid continued IV fluid shortagesnews2022-02-03T14:05:40+00:00February 3rd, 2022|Fierce Pharma|
After disastrous start to launch, Biogen still expects ‘minimal’ sales from Aduhelm this yearnews2022-02-03T13:47:34+00:00February 3rd, 2022|Fierce Pharma|
